Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Kuros Biosciences AG (KURN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
29.940 -0.800    -2.60%
14:22:08 - Delayed Data. Currency in CHF
Type:  Equity
Market:  Switzerland
ISIN:  CH0325814116 
VALOR:  32581411
  • Volume: 201,837
  • Bid/Ask: 29.920 / 30.000
  • Day's Range: 29.300 - 31.280
Kuros Biosciences 29.940 -0.800 -2.60%

Kuros Biosciences AG Company Profile

 
Get an in-depth profile of Kuros Biosciences AG, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

122

Equity Type

ORD

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Contact Information

Address Wagistrasse 25
Schlieren, 8952
Switzerland
Phone 41 44 733 4747
Fax 41 44 733 4740

Top Executives

Name Age Since Title
Clemens A. van Blitterswijk 64 2017 Chairman
Oliver Walker 55 2018 Independent Non-Executive Director
Ralph Müller - - Member of Advisory Board
Cato T. Laurentin - - Member of Advisory Board
Faheem A. Sandhu - 2018 Member of Strategic Advisory Board
W.R Walsh - 2018 Member of Strategic Advisory Board
Norbert Boos - - Member of Advisory Board
Kornelis Poelstra - 2018 Member of Strategic Advisory Board
Alpesh A. Patel - 2018 Member of Strategic Advisory Board
Andrew A. Sama - 2018 Member of Strategic Advisory Board
Richard Allen - 2018 Member of Strategic Advisory Board
Albert Arp 56 2024 Director
Thomas Cha - 2022 Member of Strategic Advisory Board
Joost D. de Bruijn 59 2017 President of Innovation and Strategy & Executive Director
Christopher T. Fair 55 2022 CEO & Director
Kimberley A. Elting 60 2025 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KURN Comments

Write your thoughts about Kuros Biosciences AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email